APIKSABANA in English translation

• apixaban

Examples of using Apiksabana in Slovenian and their translations into English

V klinični študiji pri bolnikih z atrijsko fibrilacijo so pri sočasni uporabi apiksabana z močnimi induktorji CYP3A4 in P-gp opazili zmanjšano učinkovitost in večje tveganje za krvavitve v primerjavi z uporabo apiksabana samega.
In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone.

je srednjo vrednost AUC apiksabana povečal za 1,5-krat, srednjo vrednost Cmax pa za 1,6-krat.
1.6-fold increase in mean apixaban AUC and Cmax, respectively.

Koncentracije apiksabana v plazmi se lahko zmanjšajo tudi pri sočasni uporabi drugih močnih induktorjev CYP3A4
The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers(e.g., phenytoin, carbamazepine,

Pri sočasni uporabi enkratnih odmerkov apiksabana(10 mg) in naproksena(500 mg),
Coadministration of single doses of apixaban(10 mg)

alternativa nefrakcioniranemu heparinu, saj varnost in učinkovitost apiksabana v teh kliničnih stanjih nista bili dokazani.
pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.

Pri in vitro študijah niso ugotovili zaviralnega učinka apiksabana na aktivnost CYP1A2,
In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2,

Učinkovitost apiksabana pri začetnem zdravljenju VTE je bila konsistentna med bolniki, zdravljenimi zaradi PE(relativno tveganje 0,9; 95% IZ(0,5,
Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE[Relative Risk 0.9;

Pri sočasni uporabi tovrstnih zdravil odmerka apiksabana ni treba prilagajati,
No dose adjustment for apixaban is required during concomitant therapy with such medicinal products,

ledvic(očistek kreatinina 51-80 ml/min) so bile plazemske koncentracije apiksabana(AUC) za 16%,
severe(creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations(AUC)

placeba) za dokazovanje učinkovitosti in varnosti apiksabana pri zdravljenju GVT in/ali PE(AMPLIFY)
was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE(AMPLIFY),

Pri sočasni uporabi tovrstnih zdravil odmerka apiksabana ni treba prilagajati,
No dose adjustment for apixaban is required during concomitant therapy with such medicinal products,

Učinek apiksabana na druga zdravila.
Effect of apixaban on other medicinal products.

Ena filmsko obložena tableta vsebuje 2,5 mg apiksabana.
Each film-coated tablet contains 2.5 mg apixaban.

Zato hemodializa verjetno ne bo učinkovita pri obravnavanju prevelikega odmerjanja apiksabana.
Therefore, haemodialysis is unlikely to be an effective means of managing apixaban overdose.

V primeru prevelikega odmerjanja apiksabana se lahko poveča tveganje za krvavitve.
Overdose of apixaban may result in a higher risk of bleeding.

dabigatrana ali apiksabana na edoksaban.
dabigatran, or apixaban to edoxaban.

Skupni očistek apiksabana znaša približno 3,3 l/h,
Apixaban has a total clearance of about 3.3 L/h

Pri sočasni uporabi manj močnih zaviralcev CYP3A4 in/ali P-gp odmerka apiksabana ni treba prilagajati.
No dose adjustment for apixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.

Okvara ledvic nima očitnih vplivov na razmerje med koncentracijami apiksabana v plazmi in aktivnostjo anti-FXa.
Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.

V študiji se pojavnost večjih krvavitev pri obeh odmerkih apiksabana ni statistično razlikovala od placeba.
In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo.